前苏联专利SU1676442A3 Method for preparation of quinone derivatives

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
Quinone derivatives represented by the general formula (wherein, R' and R2, which are the same or different, refer to a hydrogen atom, methyl or methoxymethyl group, or R1 and R2 bind together to form -CH = CH-CH = CH-; R3 is a hydrogen atom or methyl group; R4 is a nitrogen-containing heterocyclic group which may be substituted; R5 is a hydrogen atom, methyl group, hydroxymethyl group which may be substituted, or a carboxyl group which may be esterified or amidated; Z is or (wherein, R' is a hydrogen atom or methyl group); n is an integer from 0 through 12, m is an integer from 0 through 3, and k is an integer from 0 through 7, providing that, when m is 2 or 3, Z and k are able to vary appropriately in the repeating unit shown in [ ] ), and the hydroquinone derivatives thereof, are novel compounds, possess improvement effects of metabolism of poly unsaturated fatty acids, parficularly two or more of inhibition of production of fatty acid peroxides, inhibition of production of metabolites in 5-lipoxygenase pathway, inhibition of thromboxane A2 synthetase, thromboxane A2 receptor antagonism and scavenging action of active oxygen species, and of use as drugs, such as antithrombotics, anti-vascular constriction agents, anti- asthma agent, antiallergic agents, therapeutics for psoriasis, agents for improvement in heart, brain and cardiovascular systems, therapeutics for nephritis, active oxygen-eliminating agents, anticancer agents, agents for improvement of control of arachidonate cascade products, etc.
公开号:SU1676442A3
申请号:SU874028912
申请日:1987-01-29
公开日:1991-09-07
发明作者:Терао Синдзи；Нисикава Кохеи
申请人:Такеда Кемикал Индастриз, Лтд (Фирма)；
IPC主号:

专利说明:

Survive under reduced pressure. Ethyl acetate f is added to the residue and the resulting crystals are collected by filtration.
The concentrate is concentrated, ethanol is added to it, and then 0.2 ml of concentrated hydrochloric acid is added. Rlst-
the thief is concentrated and the resulting crystals. The crystals are collected by filtration; 0.3 g (4tf, 9O of the hydrochloride salt I-imidazolyl) methyl -3, 5,6-trime hy-I, r-fiii ioxiiHOHj are obtained.
The physical properties and nuclear magnetic resonance spectrum of this compound are given in Table 3.
Example 11 (compound 23). A mixture of 3.6 g (17.9 mmol) (3-pyridyl) - - (2-tinil) - methanol, 2.74 g (1 8.0 mmol) of 2,3,5-trimethylhydroquinone, 2.3 ml of sugar - Tansulfukis yuty and 45 ml of dichloroethane is stirred at 60 C for 2 hours.
After cooling, an aqueous solution of sodium bicarbonate was added to the reaction mixture, the organic phase was separated and the aqueous phase was extracted with Chloroform. The extract is added to the organic veil, shaken with 50 ml of an aqueous solution of 5.8 g (21.5 mmol) of ferric chloride, and slightly basified using a native solution of sodium bicarbonate, from which the orphan phase is separated. The organic veil is washed with water, dried, concentrated and purified by silica gel column chromatography (typhapotate) to give 6.0 g (92, TO 2 P-pyridyl) - (2-yl) methyl -3,5,6-trimethyl 1, 4-benzoquinone.
The physical properties and nuclear magnetic resonance spectrum of the compound described above are given in Table 3.
Example 12. (another method of no-connection of compound 7). A solution of 1.2 g (3.7 mmol) of 2- (3-pyridyl) (2-thienyl) - methyl-3, 5,6-trimethyl 1,4 benzoquinone in 20 ml of ethanol is heated under refluxing, the peak in the presence of 24 g Raney nickel (K-6) for 5 hours. After cooling, the catalyst is removed by filtration, the fritrate is concentrated, re-dissolved in ethyl acetate and shaken with an I solution of 1.2 g of ferric chloride in 10 ml of water. The mixture is slightly alkalinized with sodium bicarbonate, the organic layer is separated from it, washed with water, dried and concentrated. The residue is purified by chromatography on a column of silica gel (ethyl acetate: and pollinated ether 1: 1) to give 0.8 g (72.5%) (3 pyridylpenthes7 - 3, 5,6-trimetar igg- 1, 4-benzoquinone (com 7).
Example 13. 7 (2,5-Dimethoxy-3,4, 6-trimethyl-phenyl) -7- (3-pyridyl) -heptanoic acid (1.0 g, 2.6 mmol)
The resulting m / min 1 is dissolved in 47% aqueous hydrogen bromide (5 ml) and the solution is heated at reflux for 2 hours. After completion of the reaction, the reaction mixture is cooled. The solution is alkalinized with sodium carbonate bicarbonate and the product is extracted with ethyl acetate. The extract is washed with water, dried and evaporated under vacuum. The hydroquinone obtained is oxidized with air and the solvent is evaporated; 7-O, 5,6-trimethyl-1, 4-benzoquinone-2-yl) -7- (3-pyridyl) heptanoic acid is obtained (0.8 g, 86.8%) after crystallization from ethyl acetate, so pl. 126-127 ° C.
In a similar way, 8- (3,5,6-tr had 1-1, 4-6 e nz ochin) 8- (3-pyridyl) -octanoic acid are obtained, mp 113-114 ° C out of 8 (2 , 5 dimethoxy- 3,4,6-grimethylphenyl) -8- (3-pyridyl) octanoic acid.
Pharmacological testing.
An example of a pharmaceutical composition:
A. Capsules
1. Compound 50 mg
2.Very fine cellulose powder 30 mg
3. Lactose 37 mg
4. Magnesium Stearate 3 mg. The ingredients are mixed and injected.
in gelatin capsules.
B.M soft capsules
1. Compound 17 50 mg
2. Corn oil 100 mg
According to the known method, components 1 and 2 are mixed and put into soft capsules.
C. Tablets
1. Compound 18 50 mg
2. Lactose 34 mg
3. Corn starch 10, 6 mg
4. Corn starch (paste) 5 mg
5. Magnesium stearate 0.4 mg
6. Calcium carboxymethylcellulose 20 mg
According to a known technique, these components are mixed downmixed using a tablet forming machine.
Experience 1. Inhibition of 5, -lipoksige nazy. U7 RBL-1 cells (rat basophilic leukemia cells) are suspended in 0.5 ml of MSM (fetal cell media). To suspension
20
add a solution containing 0.5 ml of MSM, 50 µg of arachidonic acid, 10 µg of A-23187 (calcium iofor, Ellie Lilly), add a solution of the quinone compound in ethanol at final concentration 1; 0.1; 0.01 or 0.001 micromole of the test compound, and allowed to react at 37 ° C for 20 minutes. After the reaction, 4 ml of ethanol containing 1.4 dimethoxy-2-methyl-3- (3-methoxypropyl) -naphthalene as an internal standard is added, stirred well under shaking and left at room temperature for 10 minutes. The mixture is then centrifuged for 10 minutes (2000 rpm) and the surface layer is separated. The surface layer is concentrated to dryness under reduced pressure. To the concentrate is added
0.5 ml of 60% aqueous methanol.
100 μl of this solution is subjected to high performance liquid chromatography for the quantitative analysis of 25 5-NETU (5-hydroxyecosatetraenoic acid - 1 lot). The amount of 5-hydroxyecosatetraenoic acid is analyzed by measuring the absorbance at a wavelength of 273 nm using an ultraviolet absorption monitor.
The inhibitory effect of the formation of 5-hydroxyacosatetraenoic acid is expressed as: 1 - b (a) 100, where a is the peak height or peak area due to the internal standard in the absence of a quinone compound, b is the peak height or peak area caused by the internal standard when there is quinone compound.
The results confirm the effective inhibition of the formation of 5-hydroxyecosatetraenoic acid, the data are given in Table 3.
Experiment 2. Inhibition of synthetase. With thromboxane A (THA). As a preparation of thromboxane A 2 synthetase, horse thrombocyte microsome was used that was treated with indometation (treated with indomethacin and horse platelet microsome: 1PM) according to Needleman method. To 60 µl of 1PM solution in 50 ml of Tris buffer (pH 7.5), containing 140 µg of protein, 60 µl of a raster containing the drug in various concentrations are added and kept at room temperature for 5 minutes. 100 µl of this mixture is used and added to them
(ABOUT
.five
40
50
55
-
YU
20
25 1
.with
(ABOUT
.five
40
50
five
Lna 5
Ag (THAg).
MIND cooling 0 MKJI buffer, I
containing 30 mg of prostaglandin Pl (RPN), and the mixture is at
min to get the boxer
The reaction is stopped by adding 500 µl of Tris buffer, and 50 µl of the resulting solution is subjected to radioimmunoassay for thrombox.ca, a stable metabolite TXA. - The rate of inhibition (%) of TXA2 snntatyachy is determined by the difference in the rate of formation of TBX between the untreated and treated groups,
The results of experiments with some illustrative compounds are given in Table 5.
Experiment 3. Inhibition of lipid peroxide formation in rat brain homogenous.
Method: In Spragul-Dawla D rats (males, 9-15 weeks old), anesthetized with pentobarbital (50 mg / kg intraperitoneal administration). open the veins and excise the brain tissue. The tissue is homogenized in phosphate buffer (pH 7.4) and used as a 5% homogenate (in the forest). The brain homogenate is left to react at 37 ° C for 1 hour and the amount of lipid peroxide formed is determined by the method with thiobarbi-touric acid by the Okawa method. The drug is added to the 5% homogenate before the reaction with
37 ° C
for 1 h so that
concentration - steel
or
not available
10 mol / l. Inhibition of lipid peroxide formation is expressed as the rate of inhibition as a percentage of the amount obtained in the solvent treated group (DMSO). The results are shown in table.5.
Experiment 4. Effect on the occurrence of ventricular arrhythmias under the action of a repeated perfusion target in rats.
Method: The experiment was carried out on a Spragul-Dawlaaw rat (males, 11-12 weeks of age). The rat was orally administered with medicine or water at a dose of 5 ml / kg and anesthetized with pentobarbitol (50 mg / kg, intraperitoneal injection) after 1 hour. The rats are subjected to tercoatomia under artificial respiration, and the left anterior descending coronary artery is tied up for 5 minutes, then re-filled for 10 minutes. The incidence of ventricular tachycardia, gastric fibrillation
a cop and cardiac arrest within 10 min of re-perfusion.
The results are shown in table 6. Compound 1, when orally administered at a dose of 30 mg / kg, significantly suppressed the appearance of ventricular tachycardia, ventricular fibrillation and cardiac arrest.
Experiment 5. Effect on the onset of cerebral ischemia in spontaneously hypertensive rats.
Method: A spontaneously hypertensive rat (male, 20–23 weeks of age) was orally administered a compound or water at a dose of 5 ml / kg and anesthetized with pentobarbital after 1 h. Bilateral common carotid arteries are ligated, and the length of time from ligation to seizure (convulsion, support, etc.) is measured.
The results are shown in table.7. Compound 1 when orally administered at a dose of 30 mg / kg significantly lengthens the time p, about the onset of a cerebral ischemia attack. A pumped compound exerts a protective effect against brain ischemia.
Experiment 6. The effect of reducing protein in the urine in rats in which adriamycin causes nephrosis.
Method: The experiment was carried out on a Sprague-D iwley rat (male, 5 weeks old). Adriamycin was administered intravenously at a dose of 7.5 mg / kg. After 2 weeks, urine was collected within 24 hours after water was orally administered at a dose of 10 ml / kg. The total protein content in the urine and the albumin content in the urine are determined. Rats that have a total urine protein content of 20 mg / 10 g / 24 h or more are selected for the test. One group (carrier) was administered to the control group at a dose of 10 mg / kg / day, and compound 18 to the other group was given at a dose of 50 mg / kg / day (10 ml / kg, water) once a day for 2 weeks. After treatment, the drug. For 1 week or 2 weeks, urine is collected in 24 hours to determine the total urine protein content and albumin content. After 2 weeks, blood is taken from the rat sternal aorta under anesthesia with pentobarbital (50 mg / kg, intraperitoneal injection) to determine the level of plasma cholesterol.
The results are shown in table.8. Complete protein in the urine in the control
Ian group has got through 2 weeks of treatment compared to the value before treatment, and urinary albumin increases both after 1 week and 2 weeks after treatment compared to the value before treatment. In the group of compound 18, neither the total protein in the urine nor the urinary albumin differs from the corresponding values prior to treatment. In addition, the serum cholesterol level after 2 weeks is markedly reduced by treatment with compound 18. These results prove that compound 18 improves the state of nephrosis caused by adriamycin.
Experiment 7. Effect of improving glomerulenephritis in rats.
Method: Jade rats are obtained according to the Matsunag method, using Sprague-Dawley rats (males, 5 weeks old). The rat was first immunized by subcutaneous injection of a mixture of 3 mg of rabbit serum albumin and an equal volume of full Freund's supplement, and 2 weeks after this intravenous rabbit serum albumin was administered at a dose of 1 mg / rat three times a week for 8 weeks. Urine is then collected in 24 hours to determine total urine protein and urivial albumin. For the experiments, rats are taken in which the total protein in the urine is 20 mg / 80 g / 24 h or more. The control group receives one water (vehicle) at a dose of 10 ml / kg / day, and the other group receives compound 18 at a dose of 50 mg. / kg day (10 ml / kg, water) once a day for 2 weeks. After 1 or 2 weeks of treatment, urine is collected in 24 hours to determine total urine protein and urinary albumin.
The results are shown in table.9. Compared to the control group, Compound 18 shows a decrease in total protein in urine and uri-paired albumin. These results prove that compound 18 improves jade.
Experience 8. Antagonism of the thromboxane receptor).
Method: Spiral strip from the rabbit aorta (2-3 mm wide, about 3 cm long) is suspended in Krebs-Henzeleit solution with a load of 2 g. Krebs-Henzeleit solution is saturated
95% 0-5% CO and (gas mixture) are heated at 37 ° C. Inhibition of vascular strip contractions caused by the thromboxane receptor mimetic substance L, U 46619 (tO mol / l) is investigated, during preliminary treatment with compound 13 for 30 min before that.
The results are shown in table 10. Compound 13 inhibits vascular contraction. caused by U - 46619, by 14% at ≤ l / l and by 86% at a concentration of Yu mol / l, which indicates a significant antagonism of the thromboxane A2 receptor.
Experience 9. Toxicological study in rats.
Method: use (5-week-old male Wiscar mice. Rats were orally administered the compound 18 times a day for 14 days at doses of 100 and 300 mg / kg / 10 ml of water in suspension with 5% gum arabic. Control the rats were given one vehicle (10 ml / kg of water). After two weeks of treatment, after the last dose, the rats were starved overnight, and then anesthetized with ethyl acetate and the blood from the abdominal aorta was collected into a heparin-treated syringe, the plasma was separated for blood chemistry tests. Blood parameters such as total protein, glucose, calcium, urea nitrogen, creatinine, total cholesterol, total bilirubin, alkaline phosphatase (ALP), leucine aminopeptidase (IAP), lactate dehydrogenase (LDH), glutamine oxalouracine transaminase (GOT), glutamine – pyruvoline transaminase C (GPT) creatine phosphokinase (IBS), albumin and the A / G ratio (A / C) are analyzed using an autoanalyzer (Hitachi 716). Organs that act like the liver, kidneys, heart, lungs, spleen, adrenal glands, thymus, eggs, brain and pituitary, were cut and weighed. Some organs (liver, kidney, heart, lung, spleen) are fixed in a 10% neutral formalin solution for histological studies. The bone marrow is also fixed without weighing. These fixed organs are also stained with hematoxylin-eosin for histological studies.
Results: Rats that receive compound 18 (300 mg / kg) have a tendency to bear ifi.i, but the change is insignificant (t. | Bp.11). Both doses (SO and 300 mg / kg) do not make a significant change in the weight of any organ (Table 9) and HI-ryut ICMG-nFnium in blood chemistry (Table 10). R group, in which 300 mg / kg of compound 18 is administered, one of the five rats exhibits weak splenomegaly and increased extramedullary hematopoiesis. Other organs do not show changes (Table 13).
The resulting compounds have little toxicity and low side effects, therefore, the compounds themselves or pharmaceutical compositions obtained by mixing them with known pharmaceutically acceptable carriers or excipients or the like. (for example, tablets, capsules, including soft capsules and microcapsules, liquid preparations, injections, suppositories) can be safely administered orally or parenterally. The dose is varied depending on the patient to be treated, the route of administration, the symptoms, etc. For example, when administered orally to an adult patient with thrombosis, the unit dosage is usually 0.1 to 20 mg / kg of live weight, preferably 0.2 to 10 mg / kg of live weight, which is desirable to be given 1-3 times per day.
Getting the original compounds. Example 14. A solution of 10.0 g (63.3 mmol) of 3-bromopyridine in 100 ml of ether is cooled to -78 ° C, and 40 ml (64 mmol) of a 1.6 mol / l solution is added dropwise to it with stirring. n utility in hexane. After the addition is complete, the mixture is stirred for another 1 hour at a temperature of from -78 to room temperature. An aqueous solution of ammonium chloride was added to the reaction mixture, and the resulting substance was extracted with ethyl acetate. The extract is washed with water and dried, and the solvent is evaporated. The residue is purified by silica gel column chromatography (CHCl 2: MeOH 9: 1) and recrystallized from a mixture of ethyl acetate and isopropyl ether to obtain 8.0 g (77%) of 4- (3-pyridyl) -4-oxobutanol, melting point 36-37e WITH.
Similarly, 5- (3-pyridyl) -5-oxopentanol (/ 1%) and 6- (3-pyridyl) -6-oxohexanol (57%) are obtained from o -
1 1676
valerolak gona and ich, -caprolacchon, respectively.
Example 15. A solution of 12.5 g (69.8 mmol) of the alcohol derivative obtained in Example 14 and 12.6 ml (90.7 mmol) of griehylamine in 100 ml of dimethylformamide is cooled with ice and added dropwise to it medically. m at a stirring of 1.1 g (83.8 mmol) tnmetil, xjiopcujiana. The mixture is stirred for 10 minutes after the end of the addition and rachbarcampin, from the obtained CMC-s product is extracted with ethyl acetate. The extract is washed with water, dried and the solvent is evaporated. The residue is distilled off by iodine at a pressure that gives 13.4 g (76.67) 1 (3 pyridine) -4-trimethylsilyloxybutan-1-one (bp, at 1 mm Hg 126-130 ° C) .2
1 - (3-pyrid1sh) 5 and 1 SSCHLOXYIH-Tan-1-in (ie, cnp gfi 1 mm org. Line 134-138 ° C), CRH; OH-B-trimethylsil-LILKS. ON ex, H1-1-op (.kii. At 1 mm 2 Hg, 4f -16 i0O.
Example 16. Reagent 1pc pa is prepared from 7.7} 1 (29.3 mmol) 1-bromo- 2, 5-dit gsn--) 5 6-trnmethokebenchola, / 00 MI-, 8 mmol) of magnesium and 50 ml of those i of rapsphfuran at 65 ° C and the pact obtained is cooled to 0 ° C. To this solution 1 solution with stirring 6.0 g (23.9 pmoch) i of the nanoparticulate derivative, in the example 1), in 10 ml of TC of the Gruldgch Furan. The mixture is stirred at one temperature for 1 hour, i.e., until the end of the addition, to it is up to 1P. MPOT, and the mixture is extracted with a chacetate. Washing extract l. 1 and cvi-i ir (MgSO), the solvent evaporates. To the residue are added 1 Ct m (0 ml) and h. The solution is salt ns Mi h-in (10 ml), the mixture is mixed and the mixture is i-5 for 1 h. The reaction mixture is tu h -rchu under reduced pressure and the first nPmog bicarbonate naipi., w according to that {onnop mixture of the product
extrate nru-, t i j 1 inimate. The extract npoiii ifl chn T an t and n dried, and the solvent is evaporated. The residue was dissolved in 80 ml of acetic acid, to the solution was added 1S mp of sulfuric acid and a mixture of powder at 80 ° C for 30 mnch. MPL cooling and careful addition of 60 g of sodium bicarbonate with water, from the mixture of the product h1.
2
lh
Q 20
25
zo Q dz
50
five
Tom. Extra, ii i is heated with an aqueous solution of sodium bicarbonate and then with water and dried with MgSO4, the solvent is evaporated from the resulting mixture. The residue is purified by chromatography on a syngaugech column (CHCl: ELOAc 1: 1) to give 6.09 g (63.8%) of 1-acetoxy-4 (2,5-dimethoxy-3, 4,6-trimethylphenyl) - b- ( Z-pyridyl) -Zdbuten (oil).
In a similar way, 1-atstoxy-5- (2,5-dimethoxy-3,4,6-tri methylphenyl) 5 (3 pyridyl) 4-pentene n 1-acetoxy-6- (2,5-dimethoxy-3, 4,6-grimethylphenyl) -6- (3 pyridyl) -5-hexane.
Example 17 “A solution of 1.0 g (2.7 mmol) of the butene derivative obtained in Example 16 in 10 ml of acetic acid is subjected to catalytic reduction at 80 ° C in the presence of 0.4 g of 5% palladium-carbon as catalyst. After completion of the reaction, the catalyst was successful in filtration, and the filtrate was concentrated under reduced pressure. The residue is dissolved in ethyl acetate, washed with an aqueous solution of sodium bicarbonate, and then with water and dried, and the solvent is evaporated from the resulting mixture. The residue is purified on a column of silica gel (ethyl acetate) to obtain 750 mg (74.6%) of 1-acetoxy-4- (2.5 dimethoxy-3,4,6-trimethylphenyl) -4- (3-pyridyl) butane ( butter).
In a similar way, 1-acetoxy-6- (2,5-dimethoxy 3,4,6-tri-methylphenyl) -b- (3-pyridyl) hexane and 1-acetoxy-5- (2.5 dimethoxy-3, are prepared 4,6-trimethylphenyl) -5-3-pyridyl) -pentane.
Example 18 To a solution of 0.7 g (1.88 mmol) of the butane derivative obtained in Example 17 in 3 ml of methanol was added a solution of 0.3 g (7.50 mmol) of sodium hydroxide in 3 mt of water and the mixture was stirred at room temperature over 30 minutes, then water is added. The product is extracted with ethyl acetate and the extract is washed with RODAE, dried and concentrated. The residue is purified on a short column of silica gel (ethyl acetate) to give 0.5 g (80.5%) 4 (2.5 dimethoxy-3,4,6 trimethylphenyl) -4- (3 pyridyl) -1-butara (oil ).
In a similar way, 5- (2,5-dimethoxy 3,4,6-grimethylphenyl) -5- (3 pyridyl) -1-pentanol (mp. 99–10 ° C) and 6- (2.5 pimethoxy 3 , 6,6-trimethylphenyl) 6- (3-pyridyl) 1-hexanol (mp 90-91 ° C).
Example 19. A solution of 10.0 g (63.3 mmol) of 3 bromopyridine in 100 ml of ether is cooled to -78 ° C, and 40 ml of 1.6 mol / l (64 mmol) of a hexane solution of n-bu are added dropwise to the mixture. - Tillity. The mixture is stirred for 15 minutes after the end of adding to it a solution of 7.25 g (67.7 mmol) of heptanitrile in 15 ml of ether is added dropwise, and the mixture is stirred at room temperature from -78 ° C to room temperature for another 1 hour. (An aqueous solution of ammonium chloride was added to the reaction mixture and the product was extracted with ethyl acetate from the mixture. The extract was washed with water and dried, and the solvent was evaporated. The residue was purified by silica gel column chromatography (eluted with isopropyl ether), 3.9 g (36%) were obtained 3 -heptanoylpyridine (oil).
Similarly, 3 propionylpyridine and 3-pentanoylpyridine are obtained by reaction with propionitrile and valeronitrile, respectively.
Example 20. Grignard reagent is obtained from 693 mg (28.3 g atom of) magnesium, 7.6 g (29.3 mmol) of 1-bromo 2.5-dimethoxy-3,4,6 trimethylbenzene and tetrahydrofuran at 65 ° C and the mixture is cooled to 0 ° C, a solution of 3.75 g (21.9 mmol) of 3-heptanoylpyridine in 10 ml of tetrahydrofuran is added dropwise to it. After the addition is complete, the reaction mixture is stirred at room temperature for 1 h, water is added to it and the mixture is extracted with ethyl acetate. The extract is washed with water, dried and concentrated. The residue is purified by chromatography on a silica gel column (isopropyl ether) and recrystallized from hexane to give 3.2 g (30%) of 1- (2.5 dimethoxy-3,4,6 trimethylphenyl) -1- (3-pyridyl) heptanol, m.p. 109-110 C.
In a similar way, 1- (2,5 dimethoxy 3,4,6-trimethylphenyl) -1- (3-pyridyl) propanol and 1- (2,5-dimethoxy-3,4,6-trimethylphenyl) (3- pyridyl) pentanol.
Example 21. To a solution of 2.5 g (6.74 mmol) of the alcohol derivative obtained in Example 20 in 20 ml of acetic acid are added 2.5 ml of concentrated sulfuric acid and the mixture is heated at 80 ° C for 1 h After cooling, carefully add
6.8 g of potassium carbonate, a mixture of plt Ptl is water and extracted with ethyl acetate. The extract is washed with water, with an aqueous solution of sodium bicarbonate and dried, and the solvent is evaporated from the mixture. Purification on a short column of snigel (isopropyl ether) gives 2.2 g (92.5%) of 1- (2.5 dimethoxy 3,4,6 trimethylphenyl) -1- (3-pyridyl) -1-heptogen.
Example 22. The heptenic derivative obtained in Example 21 in an amount of 1.2 g (3.4 mmol) of hydrogenic acid in 12 ml of acetic acid in the presence of 0.6 g of 5% palladium carbon at 80 ° C, The reaction mixture is analyzed by token-layer chromatography. After completion of the reaction, the catalyst was removed by filtration, and the filtrate was concentrated, ethyl acetate was added to it, and it was washed with a saturated aqueous solution of sodium bicarbonate. The organic phase with a tub, evaporated from the solvent. The residue is purified by silica gel column chromatography (isopropyl ether: hexane 2: 1), to obtain 1.1 g (91.2%) of 1- (2,5-dimethoxy-3,4,6-trimethylphenyl) 1- (3 -pyridyl) heptane (oil).
In a similar way, 1- (2,5-dimethoxy-3,4,6-trimethylphenyl) -1- (3-pyridyl) propane and 1- (2,5-dimethoxy-3,4,6-trimethylphenyl) - 1- (3 pyridyl) pentane.
Example 23. A solution of 525 mg (1.6 mmol) of the butanol derivative obtained in Example 18 and 0.33 ml (2.4 mmol) of triethylamine in 3.5 ml of dichloromethane was cooled to 0 ° C and added to the mixture with stirring 0.15 ml (1.94 mmol) of methanesulfonyl chloride. The reaction mixture is stirred at the same temperature for 30 minutes, water is added to the mixture and the organic layer is separated, the aqueous layer is extracted with dichloromethane, and the extract is mixed with the described organic layer. The resulting organic layer is washed with water, dried and concentrated. The residue was dissolved in 5 ml of dimethyl sulfoxide, 148 mg (2.9 mmol of sodium cyanide) were added to it, and the mixture was stirred at 80 ° C for 2 hours. Water was added to the reaction mixture, and the product was extracted with ethyl acetate. After drying, the solvent is evaporated from the mixture. The residue is purified by chromatography.
on the column of gelicagel, get 445 mg (82.5%) 4 cyano 1 (2.5 dimetho-, 4, 6-trimsts femil) -1 - (3 pyridyl) - butane (oil).
In an anatomic manner, 5-cyano-1- (2,5-dims-tokei-3, 4,6 trimethylphenyl) 1- (3-pyridip) pentane (oil), 6 cyano 1 (2.5 dimethoxy 3,4,6 trime tylphenip) -1 (3-ppridil) hexane (oil) and 7-cyano-1- (2,5 dimethoxy-3,4,6-trimestilphenyl) -1- (3 pyrndyl) -heptane ( butter).
Example 24. To a solution of 445 mg (1.32 mmol of cyanopropane, semi-precious in example 23, in 3 ml of methanol, a solution of 1.5 g (37.5 mmol) of sodium hydroxide in 5 ml of iodine is added and the mixture is heated with a cold for 3 h. The reaction mixture is cooled, diluted with water, neutralized with 2N hydrochloric acid solution and extracted with ethyl acetate. The extract is washed with a node, dried and concentrated. The residue is purified by chromatography on a sylpagel column (CHClI: MeOH 9: 1) to give 400 mg (85.1%) of 5 (2,5-dimethoxn-3,4,6-trpmethylphenyl) -5- (3-pyridyl) pentanoic acid, mp 82-84 ° C.
In a similar way, fc (2,5-dime, toxi-3,4, 6 trimethylphenyl) -6- (3-pyridyl) hexanoic acid (m.p.183-184 ° C), 7- (2,5-dimethoxy 3,4,6-trimethylphenyl) -7- (3-pyridyl) -heptanoic acid (oil) and 8- (2,5-dimethyl- 3,4,6-trigtilfsnil) -8- (3-pyridyl) octane acid (oil).
EXAMPLE 23 A solution of 5.0 g (17.8 mmol) of 2-bromo-1,4-dimethoxy-3-methylnaphthalene in 30 ml of tetrahydrofuran is cooled to -78.degree. C. 11.2 ml (17.9 mmol) of a 1.6 mol / l solution of n-Stpllithium solution in hexane, and the mixture is stirred at the same temperature for 10 minutes after the addition is complete. Then 1.3 g (17.8 mmol) of dimethylformamide are added dropwise to the reaction mixture and the mixture is stirred at room temperature for 1 hour after completion of the addition. Water was added to the reaction mixture, and the product was extracted with ethyl acetate from the mixture. The extract is washed with water, dried and concentrated. The residue was purified by silica gel column chromatography (hexane: isopropyl ether 8: 2) and crystallized from a mixture of hexane and isopropyl ether.
five
ten
15

0 5 30
644220
ether, gender 1 i .1 2.0 g (48.9%) 2-form-mil-1,4 dimsyoxy 3-methyl n phthaline, mp ..
Example 26. A solution of 1.0 g (2.82 mmol) of a heptenic derivative obtained in Example 21 was cooled in ice and 20 ml of a mixture of acetonitrile and water (1: 1), and 4 was added dropwise to the mixture with stirring, 1 g (7.48 mmol) of ammonium cerium nitrate or 15 ml of a mixture of acetonitrile and water (1: 1). The mixture was stirred at the same temperature for 30 minutes after addition, slightly basified with aqueous sodium bicarbonate solution, and extracted with ethyl acetate. The extract is washed with water and dried, the solvent is evaporated. The residue is separated by silica gel column chromatography (isopropyl ether): 313 mg of (E) -1- (3,5,6-trimethylbenzoquinone-2 yl) -1- (3-pyridyl) heptane are eluted first and then eluted 395 mg of (Z) -1- (3,5,6-trimethylbenzoquinone-2-yl) -1- (3-pyridyl) heptene.
Similarly, (E), (Z) 7 (3,5,6 trimethylbenzoquinone-2 yl) 7 (3-pyridyl) heptenoic acid is obtained.
The physical parameters of the compounds described are given in table 4.
Example 27. In the amount of 9.00 g (50 mmol), 1,4-dimethoxy-2,3,5-trimethylbenzene was dissolved in (60 ml) and stirred under ice cooling. After adding 14.4 g (5 mmol) of dichloromethyl methyl ether, 13.8 ml (50 x 2.5 mmol) of titanium tetrachloride dissolved in CH2Cl2 (30 ml) are added dropwise with stirring over 15 minutes. After stirring for another 15 minutes under ice cooling, the ice bath was removed and the mixture was stirred at room temperature for 4 hours. The reaction mixture was poured into crushed ice (approximately 200 g) and vigorously stirred for 30 minutes. The CH CH2 layer is washed with water (3 times) and dried (ygS04), and the mixture is evaporated. The residue is recrystallized from a mixture of isopropyl ether and hexane (1: 1), to obtain 6.18 g of 2,5-dime-3,4,6 trimethylbenzaldehyde. The mother liquor is concentrated, the residue is purified by chromatography on a column of silica gel (60 g) (epyuirut isopropyl ether), get 3,70 g 2,5-
dimethoxy-3, 4, 6-trimethylbenzaldehyde. Yield 9.88 g (95%), m.p.
To a solution of 20 g (96 mmol) of 2,5-di-methoxy-3,4,6-trimethylbenzaldehyde in 200 ml of ethanol was added 1.8 g (47.6 mmol) of sodium borohydride and the mixture was stirred for 30 minutes. Salt is added to the reaction mixture and the product is extracted with ethyl acetate. The extract is washed with water and dried, and the solvent is evaporated from it under reduced pressure. The residue was crystallized from isopropyl ether to obtain 18.6 g (92.1%) of 2.5 dimethoxy-3,4,6-trimethylbenzyl alcohol, mp 121-122 ° C.
A solution of 16.5 g (78.5 mmol) of 2,5-dimethoxy-3,4,6-trimethylbenzyl alcohol in 90 ml of tetrahydrofuran is cooled to 0 C, 14.2 g (52.5 g mmol) phosphorus tribromide. After stirring at the same temperature for 30 minutes, the reaction mixture is diluted with water and extracted with isopropyl ether. The extract is washed with a saturated aqueous solution of sodium bicarbonate and dried, and the solvent is evaporated from the resulting mixture. The residue is recrystallized from methanol to obtain 17.2 g (80.0%) of 2,5-dimethoxy-3,4, (- trimethylbenzyl bromide, mp.71-72 ° C.
A solution of 15.5 g (98.1 mmol) of 3-bromopyridine in 200 ml of ethyl ether is cooled to -78 ° C, 61.3 ml (98.1 mmol) n butyl lithium (1, 6 mol / l solution in hexane). Within 20 minutes after the end of the addition, the mixture is stirred at the same temperature, and then a solution of 26.8 g (98.1 mmol) of 2,5-dimethoxy-3,4,6-trimethylbenzyl bromide in 100 ml is added dropwise. ethyl ether. After stirring for 1 hour at -78 ° C to room temperature, the reaction mixture is diluted with water and extracted with ethyl acetate. Then the extract is back extracted with 2N. hydrochloric acid solution, the aqueous layer was slightly basified with a saturated aqueous solution of sodium bicarbonate and extraction was performed with ethyl acetate. The extract is washed with water, dried and concentrated. The residue is purified by silica gel column chromatography (ethyl acetate) to obtain 22.8 g (85.8%) of 3- (2.5 dimethoxy 3,4,6-trimethylbeneyl) pyridine.
In a similar way ISTRP. - formip-1, 4-dimethoxy-V-mp and pmft shn as the starting tujmecvn.i and intermediate compounds (1, i-dm-methoxy-3 methylnapht p 1 -methanol (m.p. 122-1 21 ° С , and 2- (1, 4 dimetcgp-1 methplnafthyl) -methic bromide (so pl. 7 (| 80 ° C) is synthesized 3-Ј (, 4-dimotok-si-3 methylnaphthyl 5 -methyl pyridn.
Example 28. To a solution of 490 mg (7.33 mmol) of imidazole and 2.0 g (7.33 mmol) of 2,5-dimethoxy}, 4, h-trimethylbenzyl bromidl in 12 ml of dimoylphenmamide was added 1.2 ml tri-chtilamine, and the mixture is stirred at room temperature for 1 hour. The reaction mixture is diluted with water and extracted with ethyl acetate. Txtrum is washed with water and dried, and the solvent is evaporated. The residue is purified by chromatography on a dowel column (chloroform: methanol 1: 1) and the isopropyl is recrystallized. ether, receive 0, g (47.37,) 1 (/, .- dimethoxy-3, 4, 6-trnmetilbrnchil) ng1nd, 1 ash, mp 82-83 ° C.
Example 29, To rewind mN with tetrahydrofuran solution (40 ml) of 7- (2.5 dimethoxy-3,4,6-trn-methylphenyl) -7- (3-pyridyl) gentaic
The acid (3.0 mg, 7.8 mmop) obtained in Example 24, under ice cooling, is aluminum hydride lit1, t (450 mg, 11.9 mmol). The reaction mixture is heated to room temperature and stirred for 30 minutes. Thereafter, water is carefully added to the reaction mixture and the product is extracted with ethyl acetate. The extract is washed with water, dried and evaporated under vacuum, receive. 7- (2,5-dimethoxy-3,4,6-trimethylphenyl) 7- (3-pyridyl) heptanol (2.3 g, 79.6 / 0 as an oil after chromatography of the crude product on a silica gel.
Table 12 shows the results of tests on the biological activity of compounds 18, in table 14 comparative data on biological activity with known compounds.
Thus, the method allows to obtain quinone derivatives with low toxicity and possessing the ability to inhibit snromtase thromboxane A, thromboxan receptor Al antagonism, so they can be used in medicine for the treatment of
and prevention of diseases in mammals, such as thrombosis, coronary diseases caused by contraction or twitching of arterial smooth muscle in the heart, lungs, brain and kidney, nephritis, pulmonary insufficiency, bronchial asthma, psoriasis, inflammation, immediate allergies, arteriosclerosis, fatty tissue hepatitis, cirrhosis of the liver, hypersensitive pneumonitis, immunodeficiency, diseases of the cardiovascular system (myocardial infarction, brain stroke, nephritis, etc.), due to disorders of tissues, enzymes and cells caused by active particles of oxygen (peroxides, hydroxide radicals, lipid peroxides, etc.), and cancer, and they are useful as drugs such as antithrombotic agents, anti-vasoconstriction, anti-asthma, anti-allergic agents, therapeutic agents against psoriasis, remedies for improving the performance of the heart, brain and cardiovascular system, therapeutic agents for treating nephritis, means for removing active oxygen, anti-cancer agents, means for improving the control of products arachidonic cascade, etc.

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining quinone derivatives of the general formula
h;
CH- (CH2) n-tz- (CH2)
R4
where R and R are the same or different, methyl, methoxy or together form -CH-CH-CH-CH-;
R 3 methyl;
R, - pyridyl, imidazopil;
R is hydrogen COOri, CHjjOH, CH2OCOCH3;
s
R
where R is methyl, hydrogen; p 0-6;
ha 0-1;
k 0.1;
characterized in that the compound of the general formula
R7
Woo
R2-Y1-CH- (CH2) (CHz) OR6 bc
where R | -R, n, m, k have the indicated meanings,
Rg is hydrogen, methyl;
Rf is hydroxyl methoxy and is reacted with an oxidizing agent.
P r and about p and to and m:
Tet on pp and s and a-
01/30/86 when Z 40
04/23/86 with Z
Jgl s
C, gH, 7N02;
butter
1.63 (3N, d, J 3.0 Hz); 1.97 SZN, S); 2.00 (6H, S): 4.50 (1H, guartet, I 6 Hz); 7.27 (1H, dd, J 7.S ,,., 5 Hz); 7.67 (1H, dt, J 7.5 (f, 1.5 Hz): I, 45 (1H, dd, J 4, 1.5 Hz); 8.4 / (1 (1, d, J 1.5 Hz).
Table 1
C27H2rN04, oil
C24H2, N04, 205-207 ° C
Ct5 l "N04l 199-201 ° С
, 82-84 С
1.30 (ZN, s, J 7.0 Hz); 1.92 (6H, S); 1.97 (3N, S); 2.03 (3N, S); 2.10 (3N, d, J 1.5 Hz); 4.25 (2H, q, J 7.0 Hz); 5.90 (1H, S); 7.17 (2H, ABd, J 7.5 Hz); 7.37 (2H, ABd, J 7.5 Hz); 7.50 (1H, dt, J 7.5, 1.5 Hz); 7.67 (1H, t); 8.47 (JH, d, J 1.5 Hz); 8.50 (1H, dd, J 5.1.1 Hz)
In methyl sulfoxide - d,.: 1.83 (3H, S); 1.90 (3N, S); 1.93 (3N, 3, J 1.0 Hz); 2.50 (2H, t); 2.70 (2H, t); 5.80 (1H, S); 7.03 (2H. D, J 7.5 Hz); 7.18 (2H, d, J - 7.5 Hz); 7.27 (1H, dd, J 7.5 ° 4.5 Hz); 7.50 (1H, dt, J 7.50, 1.5 Hz); 8.37 (211, t)
2.03 (6H, S); 2.13 (3N, d, J 1.0 Hz);
5.90 (1H, S); 7.17 (2H, d, J 7.5 Hz);
7.30 (1H, dd, J 7, -58.4.5 Hz); 7.40 (2H, d, J 7.5 Hz); 7.60 (1H, dt, J 7.5 (9; 1.5 Gp);
7.77 (1H, S); 8.47 (1H, d, J 1.5 Hz);
8.57 (W, dd, J $ 4.5, 1.5 Hz); 10.40 (1H, broad S)
1.60 (2H, t); 1.93 (3N, S); 1.97 (3N, S);
2.10 (2H, S); 2.25 (2H, t); 2.38 (2H, s,
J 6.8 Hz); 4.30 (1H, s, J 7.5 Hz);
7.27 (HI, dd, J 7.5.
4.5 Hz); 7.75 (1H.dc, J 7 ,, 1.5 Hz);
7.80 (1H, broad S); 8.43 (1H, dd, J 4.5i,
1.5 Hz); 8.53 (1H, d, J 1.5 Hz)
butter
sngon
with „and„ 1st ,,
104-105 ° C
Table
1.93 (ZN, S), 2.00 (ZN, S), 2.10 (ZN,
S), 2.20 (2H, t), 4.23 (1H, s, J - 7.5 Hz), 7.20 (1H, dd, J - 7.56,
4.5 Hz); 7.70 (1H, dc, J - 7.5, 1.5 Hz);
8.40 (1H, dd, J - 4.5 &, 1.5 Hz), 8.47
(1H, d, J - 1.5 Hz)
1.10-1.80 (4H, t), 1.93 (3N. S): 1.97 (3N, S): 2.08 (3N, S); 2,0027
sngoso
Me
C4, HtfN04, oil
ten
soon
with n „no4,
68-69C
eleven
sngon
With lL FNCXJ oil
CH2OSOME 6
ftn-fti r
60-61e C
13
COOH6,9,12 C, H, j-N04,
126-127 ° C
14
ClyHlS.NOt, 66-67 ° C
15
С, Н „М02, 57-56 ° С
sixteen
A, 7.9
C ,, N ,. 44-456С
H
hydrochloride
C, 6H, gN02Cl 188-191 ° C
H8
chlorine guide
C, jH, 6N02Cl, 164-167 ° C
Ib7b442
2H Continued table. 2
2, AO (2H, m); 3.60 (2H, s, L - 6.0 Hz); 4.23 (1H, s, J - 7.5 Hz); 7.23 (1H, dd, J - 7.5fi, 4.5 Hz); 7.70 (1H, dc, J -7, 5J, 1.5 Hz); 8.37 (1H, dd, J $ 4.5, 1.5 Hz); 8.47 (1H, d, L - 1.5 Hz)
1.20-1.80 (4H, t); 1.97 (3N, S); 2.00 (3N, S); 2.03 (3N, S); 2.13 (3H.S); 2.00 - 2.40 (2H, ha): 4.06 (2H, s, J - 6.8 Hz); 4.27 (111, s, J - 7.5 Hz); 7.27 (1H, dd, J - 7.5 (9, 4.5 Hz); 7.75 (1H, dc, J - 7.5 #, 1.5 Hz), 8.47 (1H, dd , J - 4.50, 1.5 Hz); 8.53 (W, d, J - 1.5 Hz)
1.0-1.80 (4H, t); 1.97 (3N, S); 2.00 (3N, S); 2.13 (3N, S); 1.90-2.40 (2H, t); 2.33 (2H, C, J - 6.8 Hz); 4.23 (1H, J = -7.5 Hz); 7.27 (1H, dd, J 7.5, 4.5 Hz) 7.77 (1H, dt. J $ 7.5, 1.5 Hz); 8.50
(1H, dd, J, 5, 1.5 Hz), 8.53 (1H, d, J - 1.5 Hz); 8.80 (1H, wide S)
1.20-1.70 (6H, ha); 1.97 (3N, S); 2.00 (3N, S); 2.13 (3N, S); 2.00-2.40 (2H, ha); 3.60 (211, s, L 6.0 Hz); 4.27 (1H, s, L -7, 5 Hz); 7.25 (1H, dd, J - 7.5 & 4.5 Hz) 7.75 (W, dc, J - 7.5, 1.5 Hz); 8.47 (1H, dd, J - 4.5 N $, 1.5 Hz); 8.53 (1H, d, L "
-1.5 Hz).
1.10-1.80 (6H, t); 1.97 (3N, S); 2.00 (3N, S); 2.03 (H, S); 2.13 (3N, S); 1.80-2.30 (2H, ha); 4.03 (2H, s, J - 6.0 Hz); 4.23 (2H, s, J - 7.5 Hz); 7.23 (1H, Jd, J - 7.5 4.5 Hz); 7.73 (W, dc, L - 7.5Ј, 1.5 Hz); 8.47 (W, dd, J - 4, Si1, 1.5 Hz); 8.53- (1H,
d, L - 1, 5 Hz)
1.10-1.80 (611, t); 1.93 (ZN, S); 1.98 (ZN, 2.13 (ZN, S); 1.90-2.40 (2H, p); 2.30 (2H, L 6.8 Hz); 4.23 (1H, s, L - 7.5 Hz); 7.2 (1H, dd, L 7.5 $, 4.5 Hz); 7.80 (1H, dc, -7.5, 1.5 Hz), 8.47 (W, dd, L 4,
1.5 Hz); 8.53 (1H, d, L - 1.5 Hz); 9.85 (1H
2.03 (6H, S); 2.10 (3N, S); 3.87 (2H, S); 7.20 (1H, dd, L - 4.5 S, 7.5 Hz); 7.53 (1H, dt, L - 7.5Ј, 1.5 Hz), 8.47 (1H, dd, L
-4.5, 1.5 Hz); 8.52 (1H, d, L - 1.5 Hz)
0.93 (3N, s, L “7.5 Hz); 1.97 (3N, S); 2.00 (3N, S); 2.10 (6H, S); 2.27 (2H, g, L -7.5 Hz); 4.17 (1H, t, L 7.5 Hz); 7.23 (1H, dd. L 7.5}, 4.5 Hz); 7.70 (1H, dt.
with 7.5S, 1.5 Hz); 8.40 (1H, dd, L - 4.5, 1.5 Hz); 8.47 (1H, d, L 1.5 Hz)
0.87 (ZN, s, L - 6.0 Hz); 1.30 (UN, t); 1.95 (3N, S); 2.00 (3N, 5); 2.10 (2H, S); 4.23 (W, s, L 7.5 Hz); 7.18 (1H, dd, l. $ 7.5, 4.5 Hz); 7.70 (1H, dtf; L -7, ЈЈ, 1.5 Hz); 8.40 (1H, dd, L 4.5 $, 1.5 Hz); 8.48 (1H, d, L 1.5 Hz)
1.73 (3H, d, L - 7.5 Hz); 1.90 (3N, S); 2.03 (3N, S); 2.20 (3N, S); 4.48 (1H, q, L 7.5 Hz); 7.93 (1H, dd, L - 7.5, 4.5 Hz); 8.40 (1H, d, L - 4.5 Hz); 8.67 (1H, S); 8.70 (F, d, L 4.5 Hz)
2.00 (3N, S); 2.03 (3N, S); 4.10 (2H, S);
7.92 (1H, dd, L - $ 7.5, 4.5 Hz); 8.36
(1H, d, L - 4.5 Hz); 8.70 (1H, S); 8.75
(1H, d, L - 4.5 Hz)
h with ln u i t
Note. The denominator is the number of rats used, and the numerator is the number of adults who are impaired in cardiac abnormalities. Test Factor: X Test, p 0.05; , 01.
Table 5
J3
Ih Table 7
Group
Dose, mg / kg, oral
Control group Compound 130
Note. Each group consisted of 5 experiments. T - student test: p 0.01.
Control, (water
10 ml / kg / day pe-
pral, n 7)
Complete protein in
urine, mg / 100 g / 24 h 72 ± 2870 17
Urinary Albumin 23 Ј10374-12
Whey cholesterol
terin mg / dl Compound 18 (50 mg / kg / day, orally,
Complete protein in
urine, mg / 100 g /
/ 24 h76 ± 28
55 ± 17 25 ± 10
Urinary Albumin 28 ± 14
Whey cholesterol, mg / dl
Tapping. Paired T-test in relation to nonperson before treatment pЈ0.05; p 0.01. Student's t-test in relation to the control value, 05.
34
The period of time until the occurrence of the ischemic attack T, min
122 + 20
Table 8
87 4-24
51 ± 17 131 4- 39
55 ± 17 25 ± 10
59 ± 9
31 ± 7
four
M
Control group (water, 10 ml / kg / day, orally, p 3)
Total protein in urine
mg / 100 g / 24 h 654 21
Urinary albumin
Compound 18 group (50 mg / kg / day, orally, p 4)
Total protein in the urine, mg / 100 g / 24 h 75428 374- 8 48 ± 16
Urinary albumin
Note. Paired with respect to the value before processing,, 05.
Table u
Note. Mean значение is a standard error.
U 46619: (5Z, 9OЈ, 1Y, 13E, 15S) -15-, 11 (epoxymethane) is simple -5,13-diene-1-acid.
Control: Average
Statistical error
Connection 18, 100 mg / kg:
The average
Statistical error
176,16,684 1,749 0.774 0.949 0.694
3.8
4.2
0.166 0.033 0.017 0.038 0.032
170,36,347 1,579 0,709 0,872 0,673
0,222 0,106 0,023 0,025 0,030
Table 9
654 21
33 Ј15
60 ± 20 744-9 31 ± 15 3347
45 ± 21
1715 24112
Table 11
0.166 0.033 0.017 0.038 0.032
0,222 0,106 0,023 0,025 0,030
Connection 18, 300 mg / kg:
The average
Statistical error
162,06,2641,508 0.913 0.929 0.703
8.3
0.138 0.069 0.194 0.035 0.061
Control:
0.138 0.069 0.194 0.035 0.061
Continued t bl. II
39
1M (control) 0.5 ± 0.1 51 ± 4
2M (compound 18, 100 mg / kg / day) 0.5 ± 0.0 47i 7
ZM (compound
18, 300 mg / kg /.
/ day) 0.4tO, 1 41 + 140.2840.02 149 ± 2119t1
W (control) 111 ± 27 57 + 612 ± 251 ± 103,44 ± 0, S 1,65 ± 0,07
2M (compound 18, 100 mg / kg / / day) 86 ± 22 574613 ± 144 and 53.43 ± 0.05 1, 05
ZM (compound 18, 300 mg / kg / day) 99 + 18 64f9I4i 152193.47 ± .0.13 1.73 ± 0.07
Note. Blood chemistry is shown (mean ± standard deviation).
Continued table. 12
0.32 + 0.04 1981312041
0.27 + 0.03 194 ± 3220 + 1
Spleen
Red pulp expansion
Congestion (sinus dilation)
Ekstramedullu ln gepopoiz
Atrophy of white pulp
Liver, change of parenchymal cells
Bud
Expansion of the pelvis
A heart
Change in cardiac cells
Easy bone marrow change
Erythro-Vlasta overgrowth
Note. Estimation value: - - negative; + - weak, ++ - moderate, - strong. Rat Mb died
due to an introduction error during the experiment. Male rats, 5 weeks old, were used; they received compound 18 orally for 2 weeks. Control;: trots received a solution of gum arabic at a dose of 10 ml per kg body weight.
/
Н3с уусн3
H3C Sr4CH- (CH2)} 1-R5 ° Rl
A (compound 13) N
COOH48
Table 14
87
94

类似技术:

公开号 | 公开日 | 专利标题

SU1676442A3|1991-09-07|Method for preparation of quinone derivatives

JP5755417B2|2015-07-29|Pyrazole derivative modulator of hepatocyte growth factor | activity

JP4820518B2|2011-11-24|Morpholino-substituted compound therapeutics

US8541607B2|2013-09-24|Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof

KR20160061994A|2016-06-01|Methods of Treating and Preventing Endothelial Dysfunction Using bardoxolone methyl or analogs thereof

US4757084A|1988-07-12|2,5-diaryl tetrahydrothiophenes and analogs thereof as PAF-antagonists

AU2018298253A1|2020-02-27|FXR receptor agonist

JP2007277273A|2007-10-25|Medicinal preparation including halogenated aromatic for inhibiting unwanted proliferation of mammalian cell

TW202039470A|2020-11-01|Thrβ receptor agonist compound and preparation method and use thereof

JP2009538308A|2009-11-05|Imidazoazepinone compounds

EP0154887B1|1989-01-25|New 2,5-diaryl tetrahydrothiophenes and analogs thereof as paf-antagonists

JP2003514821A|2003-04-22|Imidazole compounds used as phosphodiesterase VII inhibitors

JP2007507467A|2007-03-29|Imidazopyridine derivatives as inducible NO synthase inhibitors

CA2085687A1|1993-06-20|New bht ether compounds and their use as hypolipidemic and antiatherosclerotic drugs

US4788306A|1988-11-29|Fluorooxirane carboxylates as hypoglycemic agents

US7432306B2|2008-10-07|Method for preparing novel transcription factors and use

JP2001514668A|2001-09-11| phenyl-2- | -furanones having an oxygen linkage as a COX-2 inhibitor

EP0238883A1|1987-09-30|Oxabicycloheptane derivatives, pharmaceutical composition and use

PL226999B1|2017-10-31|3-carbamoyl-1-methylpyridinium nitrate process for its preparation and use

JP2021532190A|2021-11-25|17 Beta-Heterocyclic Digitalis Analogs for the Treatment of Heart Failure

JP2756941B2|1998-05-25|Use of 2-chloro-3-arylamino-1,4-naphthoquinone derivatives as platelet aggregation inhibitors

PL182031B1|2001-10-31|Qunolone derivative intended for treating urinary incontinence

JPH0834734A|1996-02-06|Therapeutic or preventing agent for disease caused by proliferation of smooth muscular cell

JP2005514344A|2005-05-19|Compounds and methods for transplant rejection therapy

JPH0761951B2|1995-07-05|Platelet aggregation inhibitor and thrombosis remedy containing the ingredient of Chinese cabbage as an active ingredient

同族专利:

公开号 | 公开日

DK28687A|1987-07-31|

DE3775427D1|1992-02-06|

FI870394A0|1987-01-29|

EP0234729A3|1988-01-27|

EP0234729B1|1991-12-27|

IL81264A|1990-11-05|

AU601657B2|1990-09-13|

FI870394A|1987-07-31|

JPS6345257A|1988-02-26|

NO870379D0|1987-01-29|

PT84217A|1987-02-01|

IL81264D0|1987-08-31|

AT70828T|1992-01-15|

PT84217B|1989-09-14|

US5106858A|1992-04-21|

US4985447A|1991-01-15|

KR870007119A|1987-08-14|

JPH0830061B2|1996-03-27|

AU6793387A|1987-08-06|

EP0234729A2|1987-09-02|

NO870379L|1987-07-31|

HUT44504A|1988-03-28|

DK28687D0|1987-01-20|

CN87100723A|1987-09-16|

HU198908B|1989-12-28|

CA1285562C|1991-07-02|

US4851413A|1989-07-25|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

US3929880A|1971-08-21|1975-12-30|Merck Patent Gmbh|Process for the preparation of oxocarboxylic acid amides and oxocarboxylic acids|

US4201588A|1974-04-15|1980-05-06|Eastman Kodak Company|Radiation sensitive cocomplex photoreduction element with image recording layer|

US4271083B1|1974-05-02|1988-02-09|

EP0003732B1|1978-02-01|1983-10-19|The Wellcome Foundation Limited|Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations thereof|

DE2960612D1|1978-04-12|1981-11-12|Ici Plc|Blood platelet aggregation inhibitory pyridine derivatives, pharmaceutical compositions thereof, and processes for their manufacture|

US4393075B1|1980-04-14|1989-07-04|

JPH038327B2|1982-04-13|1991-02-05|Takeda Chemical Industries Ltd|

MX9203040A|1984-08-01|1992-07-31|Takeda Chemical Industries Ltd|DERIVATIVES OF QUINONA AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM.|AT74269T|1987-07-29|1992-04-15|Takeda Chemical Industries Ltd|CELL POLLIFERATION INHIBITOR.|

US5329010A|1991-03-11|1994-07-12|Eisai Co., Ltd.|Quinone derivatives|

EP0560568A3|1992-03-13|1994-06-29|Takeda Chemical Industries Ltd|Hydroquinone derivatives and intermediates for production thereof|

US5639770A|1992-05-29|1997-06-17|Otsuka Pharmaceutical Co., Ltd.|Thiazole derivatives|

CA2112987A1|1992-05-29|1993-12-09|Masatoshi Chihiro|Thiazole derivatives|

US6133278A|1994-08-12|2000-10-17|Takeda Chemical Industries, Ltd.|Use of quinone and hydroquinone derivatives for the treatment of cachexia|

EP0719552A3|1994-12-26|1997-08-20|Takeda Chemical Industries Ltd|Pharmaceutical composition comprising a quinone derivative or a hydroquinone thereof for treating dermatitis|

US6458952B1|1999-05-19|2002-10-01|Pharmacia Corporation|Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade|

US6750342B1|1999-05-19|2004-06-15|Pharmacia Corporation|Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade|

US6664255B1|1999-05-19|2003-12-16|Pharmacia Corporation|Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade|

US6653316B1|1999-05-19|2003-11-25|Pharmacia Corporation|Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade|

US6906068B1|1999-05-19|2005-06-14|Pharmacia Corporation|Substituted polycyclic aryl and heteroaryl 1,2,4 - triazinones useful as anticoagulants|

US6867217B1|1999-05-19|2005-03-15|Pharmacia Corporation|Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade|

US7015230B1|1999-05-19|2006-03-21|Pharmacia Corporation|Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade|

US6716838B1|1999-05-19|2004-04-06|Pharmacia Corporation|Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents|

US6908919B2|1999-05-19|2005-06-21|Pharmacia Corporation|Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade|

EP2266607A3|1999-10-01|2011-04-20|Immunogen, Inc.|Immunoconjugates for treating cancer|

US6660885B2|2000-03-13|2003-12-09|Pharmacia Corporation|Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade|

DE60108948T2|2000-04-05|2005-11-03|Pharmacia Corp.|POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRONES USE AS SELECTIVE INHIBITION FROM THE COAGULATION PROCESS|

JP2004505013A|2000-04-05|2004-02-19|ファルマシア・コーポレーション|Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selectively inhibiting the coagulation cascade|

US20030236257A1|2001-04-04|2003-12-25|South Michael S.|Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the cogulation cascade|

EP1274676A2|2000-04-17|2003-01-15|Pharmacia Corporation|Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade|

US7119094B1|2000-11-20|2006-10-10|Warner-Lambert Company|Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade|

US7015223B1|2000-11-20|2006-03-21|Pharmacia Corporation|Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade|

US20040068113A1|2001-11-20|2004-04-08|South Michael S.|Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade|

CA2430037A1|2000-11-20|2002-05-30|Michael S. South|Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade|

WO2003093242A2|2001-10-03|2003-11-13|Pharmacia Corporation|Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade|

US20040082585A1|2001-10-03|2004-04-29|Pharmacia Corporation|Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade|

BR0213126A|2001-10-03|2004-08-24|Pharmacia Corp|6-membered unsaturated heterocyclic compounds useful for selective inhibition of coagulation cascade|

WO2003029216A1|2001-10-03|2003-04-10|Pharmacia Corporation|6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade|

WO2003041682A2|2001-11-13|2003-05-22|Celator Technologies, Inc.|Lipid carrier compositions and methods for improved drug retention|

US6653311B1|2002-06-25|2003-11-25|Board Of Supervisors Of Louisiana State University|5-lipoxygenase inhibitors:quinone derivatives|

US8101371B2|2007-10-18|2012-01-24|Musc Foundation For Research Development|Methods for the diagnosis of genitourinary cancer|

US8263094B2|2008-09-23|2012-09-11|Eastman Chemical Company|Esters of 4,5-disubstituted-oxy-2-methyl-3,6-dioxo-cyclohexa-1,4-dienyl alkyl acids and preparation thereof|

EP2505583A1|2011-03-29|2012-10-03|Centre National de la Recherche Scientifique|Total synthesis of redox-active 1.4-naphthoquinones and their metabolites and their therapeutic use as antimalarial and schistomicidal agents|

EP2970158B1|2013-03-15|2019-02-20|BioElectron Technology Corporation|Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

JP1954786|1986-01-30|

JP9416886|1986-04-23|

[返回顶部]